<html>
<head>
<title>Utah Legislature HB0403</title>
</head>
<body>
<div id="content">
<font face="Arial">
</font><font face="Arial" size="3">1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<center><b>ASBESTOS LITIGATION TRANSPARENCY ACT</b></font><font face="Arial" size="2"></center><br/>2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<center>2016 GENERAL SESSION</center><br/>3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<center>STATE OF UTAH</center><br/>4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<center></font><font face="Arial" size="3"><b>Chief Sponsor:  Brad R. Wilson</b></font><font face="Arial" size="2"></center><br/>5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<center></font><font face="Arial" size="3">Senate Sponsor:  </font><font face="Arial" size="2"></font><font face="Arial" size="3">____________</font><font face="Arial" size="2"></center><br/>6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <hr style="width:90%; padding: 0; border: none; border-top: thick double #333; color: #333; text-align: right" /><br/>7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>LONG TITLE</b><br/>8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>General Description:</b><br/>9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This bill enacts transparency requirements with respect to asbestos bankruptcy trust<br/>10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;claims in civil asbestos actions and establishes medical criteria and procedures for<br/>11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;asbestos- and silica-related claims. <br/>12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Highlighted Provisions:</b><br/>13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This bill:<br/>14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9656;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; requires asbestos plaintiffs to investigate and file all asbestos bankruptcy trust<br/>15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;claims and provide parties with all trust claims materials after commencement of an<br/>16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;asbestos-related lawsuit;<br/>17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9656;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;gives priority to asbestos and silica claimants who can demonstrate physical<br/>18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;impairment caused by exposure to asbestos or silica; and<br/>19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9656;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;tolls the running of statutes of limitations for persons who have been exposed to<br/>20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;asbestos or silica, but have no present physical impairment caused by the exposure. <br/>21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Money Appropriated in this Bill:</b><br/>22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None<br/>23&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Other Special Clauses:</b><br/>24&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None<br/>25&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Utah Code Sections Affected:</b><br/>26&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ENACTS:<br/>27&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<a href="#78b-6-2001">78B-6-2001</a></b>, Utah Code Annotated 1953<br/><hr>28&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<a href="#78b-6-2002">78B-6-2002</a></b>, Utah Code Annotated 1953<br/>29&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<a href="#78b-6-2003">78B-6-2003</a></b>, Utah Code Annotated 1953<br/>30&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<a href="#78b-6-2004">78B-6-2004</a></b>, Utah Code Annotated 1953<br/>31&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<a href="#78b-6-2005">78B-6-2005</a></b>, Utah Code Annotated 1953<br/>32&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<a href="#78b-6-2006">78B-6-2006</a></b>, Utah Code Annotated 1953<br/>33&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<a href="#78b-6-2007">78B-6-2007</a></b>, Utah Code Annotated 1953<br/>34&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<a href="#78b-6-2008">78B-6-2008</a></b>, Utah Code Annotated 1953<br/>35&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<a href="#78b-6-2101">78B-6-2101</a></b>, Utah Code Annotated 1953<br/>36&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<a href="#78b-6-2102">78B-6-2102</a></b>, Utah Code Annotated 1953<br/>37&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<a href="#78b-6-2103">78B-6-2103</a></b>, Utah Code Annotated 1953<br/>38&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<a href="#78b-6-2104">78B-6-2104</a></b>, Utah Code Annotated 1953<br/>39&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<a href="#78b-6-2105">78B-6-2105</a></b>, Utah Code Annotated 1953<br/>40&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<a href="#78b-6-2106">78B-6-2106</a></b>, Utah Code Annotated 1953<br/>41&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<a href="#78b-6-2107">78B-6-2107</a></b>, Utah Code Annotated 1953<br/>42&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<a href="#78b-6-2108">78B-6-2108</a></b>, Utah Code Annotated 1953<br/>43&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<a href="#78b-6-2109">78B-6-2109</a></b>, Utah Code Annotated 1953<br/>44&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<a href="#78b-6-2110">78B-6-2110</a></b>, Utah Code Annotated 1953<br/>45&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<a href="#78b-6-2111">78B-6-2111</a></b>, Utah Code Annotated 1953<br/>46&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<a href="#78b-6-2112">78B-6-2112</a></b>, Utah Code Annotated 1953<br/>47&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<a href="#78b-6-2113">78B-6-2113</a></b>, Utah Code Annotated 1953<br/>48&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<a href="#78b-6-2114">78B-6-2114</a></b>, Utah Code Annotated 1953<br/>49&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <hr style="width:90%; padding: 0; border: none; border-top: thick double #333; color: #333; text-align: right" /><br/>50&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<i>Be it enacted by the Legislature of the state of Utah:</i><br/>51&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 1.  Section <b>78B-6-2001</b><a name="78b-6-2001"></a> is enacted to read:<br/>52&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<center><b>Part 20.   Asbestos Bankruptcy Trust Claims Transparency Act </b></center><br/>53&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;78B-6-2001.</u></b>  <b>Title.</b><br/>54&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>This part is referred to as the "Asbestos Bankruptcy Trust Claims Transparency Act."</u> <br/>55&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 2.  Section <b>78B-6-2002</b><a name="78b-6-2002"></a> is enacted to read:<br/>56&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;78B-6-2002.</u></b>  <b>Legislative findings -- Purpose. </b><br/>57&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(1)  The Legislature finds that:</u><br/>58&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(a)  approximately 100 employers have declared bankruptcy at least partially due to</u><br/><hr>59&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>asbestos-related liability;</u><br/>60&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(b)  these bankruptcies have resulted in a search for more solvent companies by</u><br/>61&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>claimants, resulting in over 10,000 companies being named as asbestos defendants, including</u><br/>62&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>many small- and medium-sized companies, in industries that cover 85% of the United States</u><br/>63&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>economy;</u><br/>64&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(c)  scores of trusts have been established in asbestos-related bankruptcy proceedings to</u><br/>65&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>form a multi-billion dollar asbestos bankruptcy trust compensation system outside of the tort</u><br/>66&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>system, and new asbestos trusts continue to be formed;</u><br/>67&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(d)  asbestos claimants often seek compensation from solvent defendants in civil</u><br/>68&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>actions and trusts or claims facilities formed in asbestos-related bankruptcy proceedings;</u><br/>69&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(e)  there is limited coordination and transparency between these two paths to recovery,</u><br/>70&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>which has resulted in the suppression of evidence in asbestos actions and potential fraud; and</u><br/>71&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(f)  justice is promoted by transparency with respect to asbestos bankruptcy trust claims</u><br/>72&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>in civil asbestos actions.</u><br/>73&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(2)  This part is enacted to:</u><br/>74&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(a)  provide transparency with respect to asbestos bankruptcy trust claims in civil</u><br/>75&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>asbestos actions; and</u><br/>76&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(b)  reduce the opportunity for fraud or suppression of evidence in asbestos actions.</u> <br/>77&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 3.  Section <b>78B-6-2003</b><a name="78b-6-2003"></a> is enacted to read:<br/>78&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;78B-6-2003.</u></b>  <b>Definitions.</b><br/>79&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>As used in this part:</u><br/>80&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(1)  "Asbestos" means chrysotile, amosite, crocidolite, tremolite asbestos, anthophyllite</u><br/>81&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>asbestos, actinolite asbestos, asbestiform winchite, asbestiform richterite, asbestiform</u><br/>82&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>amphibole minerals, and any of these minerals that have been chemically treated or altered,</u><br/>83&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>including all minerals defined as asbestos in 29 C.F.R. Sec. 1910 at the time the asbestos action</u><br/>84&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>is filed.</u><br/>85&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(2) (a)  "Asbestos action" means a claim for damages or other civil or equitable relief</u><br/>86&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>presented in a civil action resulting from, based on, or related to:</u><br/>87&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(i)  the health effects of exposure to asbestos, including:</u><br/>88&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(A)  loss of consortium;</u><br/>89&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(B)  wrongful death;</u><br/><hr>90&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(C)  mental or emotional injury;</u><br/>91&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(D)  risk or fear of disease or other injury; and</u><br/>92&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(E)  costs of medical monitoring or surveillance; and</u><br/>93&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(ii)  any other derivative claim made by or on behalf of a person exposed to asbestos or</u><br/>94&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>a representative, spouse, parent, child, or other relative of that person.</u><br/>95&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(b)  "Asbestos action" does not include a claim for workers' compensation or veterans'</u><br/>96&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>benefits.</u><br/>97&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(3)  "Asbestos trust" means a:</u><br/>98&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(a)  government-approved or court-approved trust that is intended to provide</u><br/>99&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>compensation to claimants arising out of, based on, or related to the health effects of exposure</u><br/>100&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>to asbestos or asbestos-containing products;</u><br/>101&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(b)  qualified settlement fund that is intended to provide compensation to claimants</u><br/>102&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>arising out of, based on, or related to the health effects of exposure to asbestos or</u><br/>103&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>asbestos-containing products;</u><br/>104&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(c)  compensation fund or claims facility created as a result of an administrative or legal</u><br/>105&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>action that is intended to provide compensation to claimants arising out of, based on, or related</u><br/>106&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>to the health effects of exposure to asbestos or asbestos-containing products;</u><br/>107&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(d)  court-approved bankruptcy that is intended to provide compensation to claimants</u><br/>108&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>arising out of, based on, or related to the health effects of exposure to asbestos or</u><br/>109&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>asbestos-containing products; or</u><br/>110&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(e)  plan of reorganization or trust pursuant to 11 U.S.C. Sec. 524(g) or 11 U.S.C. Sec.</u><br/>111&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>1121(a) or other applicable provision of law that is intended to provide compensation to</u><br/>112&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>claimants arising out of, based on, or related to the health effects of exposure to asbestos or</u><br/>113&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>asbestos-containing products.</u><br/>114&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(4)  "Plaintiff" means:</u><br/>115&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(a)  the person bringing the asbestos action, including a personal representative if the</u><br/>116&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>asbestos action is brought by an estate; or</u><br/>117&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(b)  a conservator or next friend if the asbestos action is brought on behalf of a minor or</u><br/>118&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>legally incapacitated individual.</u><br/>119&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(5)  "Trust claims materials" means a final executed proof of claim and all other</u><br/>120&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>documents and information related to a claim against an asbestos trust, including:</u><br/><hr>121&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(a)  claims forms and supplementary materials;</u><br/>122&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(b)  affidavits;</u><br/>123&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(c)  depositions and trial testimony;</u><br/>124&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(d)  work history;</u><br/>125&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(e)  medical and health records;</u><br/>126&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(f)  documents reflecting the status of a claim against an asbestos trust; and</u><br/>127&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(g)  all documents relating to the settlement of the trust claim if the trust claim has</u><br/>128&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>settled.</u><br/>129&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(6)  "Trust governance documents" means all documents that relate to eligibility and</u><br/>130&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>payment levels, including:</u><br/>131&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(a)  claims payment matrices; and</u><br/>132&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(b)  trust distribution procedures or plans for reorganization for an asbestos trust.</u><br/>133&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(7)  "Veterans' benefits" means a program for benefits in connection with military</u><br/>134&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>service administered by the Veterans' Administration under United States Code, Title 38,</u><br/>135&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Veterans' Benefits.</u><br/>136&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(8) (a)  "Workers' compensation" means a program administered by the United States or</u><br/>137&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>a state to provide benefits, funded by a responsible employer or the employer's insurance</u><br/>138&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>carrier, for occupational diseases or injuries or for disability or death caused by occupational</u><br/>139&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>diseases or injuries.</u><br/>140&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(b)  "Workers' compensation" includes the Longshore and Harbor Workers'</u><br/>141&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Compensation Act, 33 U.S.C. Sec. 901 et seq., and Federal Employees' Compensation Act, 5</u><br/>142&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>U.S.C. Sec. 8101 et seq.</u><br/>143&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(c)  "Workers' compensation" does not include the Federal Employers' Liability Act, 45</u><br/>144&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>U.S.C. Sec. 51 et seq.</u> <br/>145&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 4.  Section <b>78B-6-2004</b><a name="78b-6-2004"></a> is enacted to read:<br/>146&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;78B-6-2004.</u></b>  <b>Required disclosures by plaintiff. </b><br/>147&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(1)  Within 30 days after an asbestos action is filed, or within 30 days after May 10,</u><br/>148&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>2016, whichever is later, and before any evidence is preserved by deposition in the asbestos</u><br/>149&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>action, the plaintiff shall do all of the following:</u><br/>150&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(a)  provide the court and parties with a sworn statement signed by the plaintiff and the</u><br/>151&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>plaintiff's counsel, under penalties of perjury, indicating:</u><br/><hr>152&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(i)  that an investigation of all asbestos trust claims has been conducted, and that all</u><br/>153&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>asbestos trust claims that can be made by the plaintiff or any person on the plaintiff's behalf</u><br/>154&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>have been filed;</u><br/>155&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(ii)  whether there has been a request to defer, delay, suspend, or toll any asbestos trust</u><br/>156&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>claim; and</u><br/>157&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(iii)  the disposition of each asbestos trust claim;</u><br/>158&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(b)  provide all parties with all trust claims materials, including:</u><br/>159&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(i)  trust claims materials that relate to conditions other than those that are the basis for</u><br/>160&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>the asbestos action; and</u><br/>161&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(ii)  all trust claims materials from all law firms connected to the plaintiff in relation to</u><br/>162&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>exposure to asbestos, including anyone at a law firm involved in the asbestos action, any</u><br/>163&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>referring law firm, and any other firm that has filed an asbestos trust claim for the plaintiff or</u><br/>164&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>on the plaintiff's behalf; and</u><br/>165&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(c)  produce all trust claims materials submitted by another individual to any asbestos</u><br/>166&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>trusts if:</u><br/>167&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(i)  the plaintiff's asbestos trust claim is based on exposure to asbestos through the other</u><br/>168&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>individual; and</u><br/>169&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(ii)  the materials are available to the plaintiff or the plaintiff's counsel.</u><br/>170&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(2)  The plaintiff shall supplement the information and materials required under</u><br/>171&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Subsection (1) within 30 days after the plaintiff or a person on the plaintiff's behalf:</u><br/>172&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(a)  supplements an existing asbestos trust claim;</u><br/>173&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(b)  receives additional information or materials related to an asbestos trust claim; or</u><br/>174&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(c)  files an additional asbestos trust claim.</u><br/>175&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(3)  The court may dismiss the asbestos action if the plaintiff fails to comply with this</u><br/>176&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>section.</u><br/>177&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(4)  An asbestos action may not proceed to trial until at least 180 days after the</u><br/>178&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>requirements of Subsection (1) are met.</u> <br/>179&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 5.  Section <b>78B-6-2005</b><a name="78b-6-2005"></a> is enacted to read:<br/>180&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;78B-6-2005.</u></b>  <b>Identification of additional asbestos trust claims by defendant. </b><br/>181&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(1) (a)  A defendant may file a motion requesting a stay of the proceedings on or before</u><br/>182&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>the later of 60 days before the date that the trial in the action is set to commence or 15 days</u><br/><hr>183&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>after the defendant first obtains information that could support additional trust claims by the</u><br/>184&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>plaintiff.</u><br/>185&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(b)  The motion described in Subsection (1)(a) shall identify the additional asbestos</u><br/>186&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>trust claims the defendant believes the plaintiff can file and include information supporting the</u><br/>187&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>additional asbestos trust claims.</u><br/>188&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(2)  Within 10 days of receiving the defendant's motion described in Subsection (1)(a),</u><br/>189&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>the plaintiff shall:</u><br/>190&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(a)  file the asbestos trust claims;</u><br/>191&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(b)  file a written response with the court stating why there is insufficient evidence for</u><br/>192&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>the plaintiff to file the asbestos trust claims; or</u><br/>193&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(c)  file a written response with the court requesting a determination that the cost to file</u><br/>194&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>the asbestos trust claims exceeds the plaintiff's reasonably anticipated recovery.</u><br/>195&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(3) (a)  If the court determines that there is a sufficient basis for the plaintiff to file an</u><br/>196&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>asbestos trust claim identified in the motion to stay, the court shall stay the asbestos action until</u><br/>197&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>the plaintiff files the asbestos trust claim and produces all related trust claims materials.</u><br/>198&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(b)  If the court determines that the cost of submitting an asbestos trust claim exceeds</u><br/>199&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>the plaintiff's reasonable anticipated recovery, the court shall stay the asbestos action until the</u><br/>200&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>plaintiff files with the court and provides all parties with a verified statement of the plaintiff's</u><br/>201&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>history of exposure, usage, or other connection to asbestos covered by that asbestos trust.</u><br/>202&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(4)  Not less than 60 days after the plaintiff provides the documentation required under</u><br/>203&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>this section, the court may schedule the asbestos action for trial.</u> <br/>204&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 6.  Section <b>78B-6-2006</b><a name="78b-6-2006"></a> is enacted to read:<br/>205&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;78B-6-2006.</u></b>  <b>Discovery -- Use of materials -- Trust record. </b><br/>206&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(1) (a)  Trust claims materials and trust governance documents are presumed to be</u><br/>207&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>relevant and authentic and are admissible in evidence in an asbestos action.</u><br/>208&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(b)  A claim of privilege does not apply to any trust claims materials or trust governance</u><br/>209&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>documents.</u><br/>210&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(2) (a)  A defendant in an asbestos action may seek discovery from an asbestos trust.</u><br/>211&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(b)  The plaintiff may not claim privilege or confidentiality to bar discovery and shall</u><br/>212&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>provide consent or other expression of permission that may be required by the asbestos trust to</u><br/>213&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>release information and materials sought by a defendant.</u><br/><hr>214&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(3)  Trust claim materials that are sufficient to entitle a claim to consideration for</u><br/>215&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>payment under the applicable trust governance documents may be sufficient to support a jury</u><br/>216&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>finding that the plaintiff was exposed to products for which the trust was established to provide</u><br/>217&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>compensation and that the exposure may be a substantial factor in causing the plaintiff's injury</u><br/>218&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>that is at issue in the asbestos action.</u><br/>219&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(4)  Not less than 30 days before trial in an asbestos action, the court shall enter into the</u><br/>220&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>record a document that identifies every asbestos trust claim made by the plaintiff or on the</u><br/>221&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>plaintiff's behalf.</u> <br/>222&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 7.  Section <b>78B-6-2007</b><a name="78b-6-2007"></a> is enacted to read:<br/>223&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;78B-6-2007.</u></b>  <b>Failure to provide information -- Sanctions. </b><br/>224&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(1)  On the motion of a defendant or judgment debtor seeking sanctions or other relief</u><br/>225&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>in an asbestos action, the court may impose any sanction provided by court rule or a law of this</u><br/>226&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>state, including vacating a judgment rendered in the action, for a plaintiff's failure to comply</u><br/>227&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>with the disclosure requirements of this part.</u><br/>228&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(2)  The trial court, on motion by a defendant or judgment debtor seeking sanctions or</u><br/>229&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>other relief, has jurisdiction to reopen the judgment in an asbestos action, adjust the judgment</u><br/>230&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>by the amount of any subsequent asbestos trust payments obtained by the plaintiff, and order</u><br/>231&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>any other relief to the parties that the court considers just and proper if:</u><br/>232&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(a)  the plaintiff or a person on the plaintiff's behalf files an asbestos trust claim after</u><br/>233&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>the plaintiff obtains a judgment in an asbestos action; and</u><br/>234&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(b)  the asbestos trust was in existence at the time the plaintiff obtained the judgment.</u><br/>235&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(3)  A defendant or judgment debtor shall file any motion under this section within a</u><br/>236&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>reasonable time, not to exceed 3 years after the judgment was entered.</u> <br/>237&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 8.  Section <b>78B-6-2008</b><a name="78b-6-2008"></a> is enacted to read:<br/>238&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;78B-6-2008.</u></b>  <b>Application. </b><br/>239&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(1)  This part applies to asbestos actions filed on or after May 10, 2016, as well as any</u><br/>240&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>pending asbestos actions in which trial has not commenced as of May 10, 2016.</u><br/>241&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(2)  This part may only be applied prospectively if the application of a provision in this</u><br/>242&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>part would unconstitutionally affect a vested right.</u> <br/>243&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 9.  Section <b>78B-6-2101</b><a name="78b-6-2101"></a> is enacted to read:<br/>244&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<center><b>Part 21.   Asbestos and Silica Claims Priorities Act </b></center><br/><hr>245&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;78B-6-2101.</u></b>  <b>Title.</b><br/>246&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>This part is known as the "Asbestos and Silica Claims Priorities Act."</u> <br/>247&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 10.  Section <b>78B-6-2102</b><a name="78b-6-2102"></a> is enacted to read:<br/>248&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;78B-6-2102.</u></b>  <b>Findings and purpose. </b><br/>249&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(1)  The Legislature finds that:</u><br/>250&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(a)  asbestos is a mineral that was widely used before the 1980s for insulation,</u><br/>251&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>fireproofing, and other purposes;</u><br/>252&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(b)  millions of American workers and others were exposed to asbestos, especially</u><br/>253&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>during and after World War II, and before the issuance of regulations by the Occupational</u><br/>254&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Safety and Health Administration in the early 1970s;</u><br/>255&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(c)  long-term exposure to asbestos has been associated with various types of cancer,</u><br/>256&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>including mesothelioma and lung cancer, as well as nonmalignant conditions such as asbestosis</u><br/>257&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>and diffuse pleural thickening;</u><br/>258&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(d)  diseases caused by asbestos often have long latency periods;</u><br/>259&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(e)  although the use of asbestos has dramatically declined since the 1970s and</u><br/>260&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>workplace exposures have been regulated since 1971 by the Occupational Safety and Health</u><br/>261&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Administration, past exposures will continue to result in significant claims of death and</u><br/>262&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>disability as a result of the exposure;</u><br/>263&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(f)  the United States Supreme Court in Amchem Products, Inc. v. Windsor, 521 U.S. </u><br/>264&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>591, 598 (1997), described the asbestos litigation as a "crisis";</u><br/>265&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(g)  attorney-sponsored x-ray screenings have been used to amass large numbers of</u><br/>266&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>claims by unimpaired plaintiffs;</u><br/>267&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(h)  approximately 100 employers have declared bankruptcy at least partially because of</u><br/>268&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>asbestos-related liability;</u><br/>269&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(i)  these bankruptcies have resulted in a search for more solvent companies by</u><br/>270&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>claimants, resulting in over 10,000 companies being named as asbestos defendants, including</u><br/>271&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>many small- and medium-sized companies, in industries that cover 85% of the United States</u><br/>272&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>economy;</u><br/>273&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(j)  silica is a naturally occurring mineral and is the basic component of sand, quartz,</u><br/>274&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>and granite;</u><br/>275&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(k)  silica-related illness, including silicosis, can develop from the prolonged inhalation</u><br/><hr>276&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>of respirable silica particles;</u><br/>277&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(l)  silica claims, like asbestos claims, have involved individuals with no demonstrable</u><br/>278&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>physical impairment, and plaintiffs have been identified through for-profit screening</u><br/>279&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>companies;</u><br/>280&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(m)  silica screening processes have been found subject to substantial abuse and</u><br/>281&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>potential fraud;</u><br/>282&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(n)  the cost of compensating plaintiffs who have no present asbestos-related or</u><br/>283&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>silica-related physical impairment, and the cost of litigating their claims, jeopardizes the ability</u><br/>284&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>of defendants to compensate plaintiffs with cancer and adversely affects defendant companies;</u><br/>285&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(o)  concerns about statutes of limitations and available funds can prompt unimpaired</u><br/>286&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>plaintiffs to bring asbestos and silica actions to protect their rights to future compensation</u><br/>287&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>should they become impaired; and</u><br/>288&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(p)  the public interest requires giving priority to the claims of exposed individuals who</u><br/>289&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>are sick in order to help preserve, now and for the future, defendants' ability to compensate</u><br/>290&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>people who develop cancer and other serious asbestos-related diseases, as well as silica-related</u><br/>291&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>injuries, and to safeguard the jobs, benefits, and savings of workers in this state and the</u><br/>292&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>well-being of this state's economy.</u><br/>293&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(2)  This part is enacted to:</u><br/>294&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(a)  give priority to asbestos and silica claimants who can demonstrate physical</u><br/>295&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>impairment caused by exposure to asbestos or silica;</u><br/>296&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(b)  toll the running of statutes of limitations for persons who have been exposed to</u><br/>297&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>asbestos or to silica, but who have no present physical impairment caused by the exposure;</u><br/>298&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(c)  enhance the ability of the courts to supervise and manage asbestos and silica cases;</u><br/>299&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(d)  reduce the opportunity for fraud in asbestos and silica litigation; and</u><br/>300&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(e)  conserve defendants' resources to allow compensation to present and future</u><br/>301&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>claimants with physical impairment caused by exposure to asbestos or silica.</u> <br/>302&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 11.  Section <b>78B-6-2103</b><a name="78b-6-2103"></a> is enacted to read:<br/>303&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;78B-6-2103.</u></b>  <b>Definitions.</b><br/>304&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>As used in this part:</u><br/>305&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(1)  "AMA Guides to the Evaluation of Permanent Impairment" means the American</u><br/>306&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Medical Association's Guides to the Evaluation of Permanent Impairment in effect at the time</u><br/><hr>307&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>of the performance of any examination or test on the exposed person required under this part.</u><br/>308&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(2)  "Asbestos" means the same as that term is defined in Section <a href="#78b-6-2003">78B-6-2003</a>.</u><br/>309&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(3)  "Asbestos action" means the same as that term is defined in Section <a href="#78b-6-2003">78B-6-2003</a>.</u><br/>310&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(4)  "Asbestosis" means bilateral diffuse interstitial fibrosis of the lungs caused by</u><br/>311&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>inhalation of asbestos fibers.</u><br/>312&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(5)  "Board-certified in occupational medicine" means a physician who is certified in</u><br/>313&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>the specialty of occupational medicine by the American Board of Preventive Medicine or the</u><br/>314&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>specialty of occupational/environmental medicine by the American Osteopathic Board of</u><br/>315&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Preventive Medicine and whose certification was current at the time of the performance of an</u><br/>316&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>examination and rendition of a report required by this part.</u><br/>317&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(6)  "Board-certified in oncology" means a physician who is certified in the specialty of</u><br/>318&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>medical oncology by the American Board of Internal Medicine or specialty of oncology by the</u><br/>319&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>American Osteopathic Board of Internal Medicine and whose certification was current at the</u><br/>320&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>time of the performance of an examination and rendition of a report required by this part.</u><br/>321&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(7)  "Board-certified in pathology" means a physician who holds primary certification in</u><br/>322&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>anatomic pathology or clinical pathology from the American Board of Pathology or the</u><br/>323&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>American Osteopathic Board of Pathology, whose certification was current at the time of the</u><br/>324&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>performance of an examination and rendition of a report required by this part, and whose</u><br/>325&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>professional practice is principally in the field of pathology involving regular evaluation of</u><br/>326&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>pathology materials obtained from surgical or postmortem specimens.</u><br/>327&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(8)  "Board-certified in pulmonary medicine" means a physician who is certified in the</u><br/>328&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>specialty of pulmonary medicine by the American Board of Internal Medicine or the American</u><br/>329&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Osteopathic Board of Internal Medicine and whose certification was current at the time of the</u><br/>330&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>performance of an examination and rendition of a report required by this part.</u><br/>331&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(9)  "Certified B-reader" means an individual who has qualified as a National Institute</u><br/>332&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>for Occupational Safety and Health (NIOSH) final or B-reader of x-rays under 42 C.F.R.  Sec.</u><br/>333&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>37.51(b), whose certification was current at the time of any readings required under this part,</u><br/>334&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>and whose B-reads comply with the NIOSH B-reader's Code of Ethics, Issues in Classification</u><br/>335&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>of Chest Radiographs, and Classification of Chest Radiographs in Contested Proceedings.</u><br/>336&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(10)  "Chest x-ray" means chest films taken in accordance with all applicable state and</u><br/>337&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>federal regulatory standards and taken in the posterior-anterior view.</u><br/><hr>338&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(11)  "DLCO" means diffusing capacity of the lung for carbon monoxide, which is the</u><br/>339&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>measurement of carbon monoxide transfer from inspired gas to pulmonary capillary blood.</u><br/>340&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(12)  "Exposed person" means a person whose exposure to asbestos or silica or to</u><br/>341&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>asbestos-containing or silica-containing products is the basis for an asbestos or silica action.</u><br/>342&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(13)  "FEV1" means forced expiratory volume in the first second, which is the maximal</u><br/>343&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>volume of air expelled in one second during performance of simple spirometric tests.</u><br/>344&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(14)  "FEV1/FVC" means the ratio of the actual values of FEV1 over FVC.</u><br/>345&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(15)  "FVC" means forced vital capacity, which is the maximal volume of air expired</u><br/>346&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>with maximum effort from a position of full inspiration.</u><br/>347&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(16)  "ILO system" and "ILO scale" mean the radiological ratings and system for the</u><br/>348&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>classification of chest x-rays of the International Labor Office provided in "Guidelines for the</u><br/>349&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Use of ILO International Classification of Radiographs of Pneumoconioses" in effect on the</u><br/>350&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>day any x-rays of the exposed person were reviewed by a certified B-reader.</u><br/>351&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(17)  "Mesothelioma" means a malignant tumor with a primary site of origin in the</u><br/>352&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>pleura, peritoneum, or pericardium that has been diagnosed by a board-certified pathologist or</u><br/>353&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>oncologist using standardized and accepted criteria of microscopic morphology or appropriate</u><br/>354&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>immunohistochemical staining techniques.</u><br/>355&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(18)  "Nonmalignant condition" means any condition that can be caused by asbestos or</u><br/>356&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>silica other than a diagnosed cancer.</u><br/>357&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(19)  "Official statements of the American Thoracic Society" means lung function</u><br/>358&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>testing standards set forth in statements from the American Thoracic Society including</u><br/>359&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>standardizations of spirometry, standardizations of lung volume testing, standardizations of</u><br/>360&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>diffusion capacity testing or single-breath determination of carbon monoxide uptake in the</u><br/>361&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>lung, and interpretive strategies for lung function tests, which are in effect on the day of the</u><br/>362&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>pulmonary function testing of the exposed person.</u><br/>363&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(20)  "Pathological evidence of asbestosis" means a statement by a board-certified</u><br/>364&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>pathologist that more than one representative section of lung tissue uninvolved with any other</u><br/>365&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>disease process demonstrates a pattern of peribronchiolar or parenchymal scarring in the</u><br/>366&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>presence of characteristic asbestos bodies graded 1(B) or higher under the criteria published in</u><br/>367&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Asbestos-Associated Diseases, 106 Archive of Pathology and Laboratory Medicine 11,</u><br/>368&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Appendix 3 (October 8, 1982), or grade one or higher in pathology of asbestosis, 134 Archive</u><br/><hr>369&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>of Pathology and Laboratory Medicine 462-80 (March 2010) (tables 2 and 3), or as amended at</u><br/>370&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>the time of the exam, and there is no other more likely explanation for the presence of the</u><br/>371&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>fibrosis.</u><br/>372&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(21)  "Pathological evidence of silicosis" means a statement by a board-certified</u><br/>373&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>pathologist that more than one representative section of lung tissue uninvolved with any other</u><br/>374&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>disease process demonstrates complicated silicosis with characteristic confluent silicotic</u><br/>375&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>nodules or lesions equal to or greater than one centimeter and birefringent crystals or other</u><br/>376&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>demonstration of crystal structures consistent with silica (well-organized concentric whorls of</u><br/>377&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>collagen surrounded by inflammatory cells) in the lung parenchyma and no other more likely</u><br/>378&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>explanation for the presence of the fibrosis exists, or acute silicosis with characteristic</u><br/>379&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>pulmonary edema, interstitial inflammation, and the accumulation within the alveoli of</u><br/>380&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>proteinaceous fluid rich in surfactant.</u><br/>381&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(22)  "Plaintiff" means the person bringing the asbestos or silica action, including a</u><br/>382&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>personal representative if the asbestos or silica action is brought by an estate, or a conservator</u><br/>383&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>or next friend if the asbestos or silica action is brought on behalf of a minor or legally</u><br/>384&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>incapacitated individual.</u><br/>385&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(23)  "Plethysmography or body (box) plethysmography" means the test for determining</u><br/>386&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>lung volume in which the exposed person is enclosed in a chamber equipped to measure</u><br/>387&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>pressure, flow, or volume change.</u><br/>388&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(24)  "Predicted lower limit of normal" means the test value that is the calculated</u><br/>389&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>standard convention lying at the fifth percentile, below the upper 95% of the reference</u><br/>390&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>population, based on age, height, and gender, according to the recommendations by the</u><br/>391&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>American Thoracic Society and as referenced in the applicable AMA Guides to the Evaluation</u><br/>392&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>of Permanent Impairment, primarily National Health and Nutrition Examination Survey</u><br/>393&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(NHANES) predicted values, or as amended.</u><br/>394&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(25)  "Premises owner" means a person, firm, or organization that owns, in whole or in</u><br/>395&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>part, leases, rents, maintains, or controls privately owned land or water, or a building and</u><br/>396&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>structure on the land or water, or that leases state-owned land or water, including a building or</u><br/>397&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>other structure on the land or water.</u><br/>398&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(26)  "Pulmonary function test" means spirometry, lung volume testing, and diffusion</u><br/>399&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>capacity testing, including appropriate measurements, quality control data, and graphs,</u><br/><hr>400&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>performed in accordance with the methods of calibration and techniques provided in the</u><br/>401&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>applicable AMA Guides to the Evaluation of Permanent Impairment and all standards provided</u><br/>402&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>in the official statements of the American Thoracic Society in effect on the day pulmonary</u><br/>403&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>function testing of the exposed person was conducted.</u><br/>404&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(27)  "Qualified physician" means a physician board-certified in oncology, pathology,</u><br/>405&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>pulmonary medicine, or occupational medicine, as may be appropriate to the actual diagnostic</u><br/>406&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>specialty in question, that meets all of the following requirements:</u><br/>407&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(a) (i)  if the exposed person is alive at the time of examination, the physician</u><br/>408&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>conducted a physical examination and has taken, or has directed to be taken under the</u><br/>409&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>physician's supervision, direction, and control, a detailed occupational, exposure, medical,</u><br/>410&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>smoking, and social history from the exposed person; or</u><br/>411&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(ii)  if the exposed person is deceased, the physician has reviewed the pathology</u><br/>412&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>material and has taken, or has directed to be taken under the physician's supervision, direction,</u><br/>413&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>and control, a detailed history from the person most knowledgeable about the information</u><br/>414&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>forming the basis of the asbestos or silica action;</u><br/>415&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(b)  the physician treated or is treating the exposed person, and had or has a</u><br/>416&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>doctor-patient relationship with the exposed person at the time of the physical examination, or</u><br/>417&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>in the case of a board-certified pathologist, examined tissue samples or pathological slides of</u><br/>418&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>the exposed person at the request of the treating physician;</u><br/>419&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(c)  the physician spends no more than 25% of the physician's professional practice time</u><br/>420&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>providing consulting or expert services in actual or potential civil actions, and whose medical</u><br/>421&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>group, professional corporation, clinic, or other affiliated group earns not more than 25% of the</u><br/>422&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>medical group's revenue providing such services;</u><br/>423&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(d)  the physician was licensed to practice on the date any examination or pulmonary</u><br/>424&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>function testing was conducted, and the physician actively practices or practiced in the state</u><br/>425&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>where the exposed person resides, or resided at the time of the examination or pulmonary</u><br/>426&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>function testing, or the state where the asbestos or silica action was filed;</u><br/>427&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(e)  the physician received or is receiving payment for the treatment of the exposed</u><br/>428&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>person from the exposed person, a member of the exposed person's family, or the exposed</u><br/>429&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>person's health care plan and not from the exposed person's lawyer or law firm;</u><br/>430&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(f)  the physician prepared or directly supervised the preparation and final review of any</u><br/><hr>431&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>medical report under this part; and</u><br/>432&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(g)  the physician has not relied on any examination, test, radiograph, report, or opinion</u><br/>433&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>of any doctor, clinic, laboratory, or testing company that performed an examination, test,</u><br/>434&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>radiograph, or screening of the exposed person in violation of any law, regulation, licensing</u><br/>435&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>requirement, or medical code of practice of the state in which the examination, test, or</u><br/>436&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>screening was conducted, or that was conducted without establishing a doctor-patient</u><br/>437&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>relationship with the exposed person or medical personnel involved in the examination, test, or</u><br/>438&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>screening process, or that required the exposed person to agree to retain the legal service of a</u><br/>439&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>law firm.</u><br/>440&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(28)  "Radiological evidence of asbestosis" means a quality 1 chest x-ray under the ILO</u><br/>441&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>system, or a quality 2 chest x-ray in a death case when no pathology or quality 1 chest x-ray is</u><br/>442&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>available, showing bilateral small, irregular opacities (s, t, or u) occurring primarily in the</u><br/>443&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>lower lung zones graded by a certified B-reader as at least 1/1 on the ILO scale.</u><br/>444&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(29)  "Radiological evidence of diffuse bilateral pleural thickening" means a quality 1</u><br/>445&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>chest x-ray under the ILO system, or a quality 2 chest x-ray in a death case when no pathology</u><br/>446&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>or quality 1 chest x-ray is available, showing diffuse bilateral pleural thickening of at least b2</u><br/>447&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>on the ILO scale and blunting of at least one costophrenic angle as classified by a certified</u><br/>448&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>B-reader.</u><br/>449&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(30)  "Radiological evidence of silicosis" means a quality 1 chest x-ray under the ILO</u><br/>450&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>system, or a quality 2 chest x-ray in a death case when no pathology or quality 1 chest x-ray is</u><br/>451&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>available, showing bilateral predominantly nodular or rounded opacities (p, q, or r) occurring</u><br/>452&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>primarily in the upper lung fields graded by a certified B-reader as at least 1/1 on the ILO scale</u><br/>453&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>or A, B, or C sized opacities representing complicated silicosis or acute silicosis with</u><br/>454&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>characteristic pulmonary edema, interstitial inflammation, and the accumulation within the</u><br/>455&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>alveoli of proteinaceous fluid rich in surfactant.</u><br/>456&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(31)  "Silica" means a respirable crystalline form of silicon dioxide, including quartz,</u><br/>457&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>cristobalite, and tridymite.</u><br/>458&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(32) (a)  "Silica action" means a claim for damages or other civil or equitable relief</u><br/>459&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>presented in a civil action arising out of, based on, or related to:</u><br/>460&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(i)  the health effects of exposure to silica, including:</u><br/>461&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(A)  loss of consortium;</u><br/><hr>462&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(B)  wrongful death;</u><br/>463&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(C)  mental or emotional injury;</u><br/>464&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(D)  risk or fear of disease or other injury; and</u><br/>465&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(E)  costs of medical monitoring or surveillance; and</u><br/>466&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(ii)  any other derivative claim made by or on behalf of a person exposed to silica or a</u><br/>467&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>representative, spouse, parent, child, or other relative of that person.</u><br/>468&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(b)  "Silica action" does not include a claim under workers' compensation law or</u><br/>469&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>veterans' benefits.</u><br/>470&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(33)  "Silicosis" means simple silicosis, acute silicosis, accelerated silicosis, or chronic</u><br/>471&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>silicosis caused by the inhalation of respirable silica.</u><br/>472&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(34)  "Spirometry" means a test of air capacity of the lung through a spirometer to</u><br/>473&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>measure the volume of air inspired and expired.</u><br/>474&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(35)  "Supporting test results" means copies of the following documents and images:</u><br/>475&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(a)  pulmonary function tests, including printouts of the flow volume loops, volume</u><br/>476&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>time curves, DLCO graphs, lung volume tests and graphs, quality control data, and other</u><br/>477&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>pertinent data for all trials and all other elements required to demonstrate compliance with the</u><br/>478&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>equipment, quality, interpretation, and reporting standards set forth in this part;</u><br/>479&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(b)  B-reading and B-reader reports;</u><br/>480&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(c)  reports of x-ray examinations;</u><br/>481&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(d)  diagnostic imaging of the chest;</u><br/>482&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(e)  pathology reports; and</u><br/>483&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(f)  all other tests reviewed by the diagnosing physician or a qualified physician in</u><br/>484&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>reaching the physician's conclusions.</u><br/>485&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(36)  "Timed gas dilution" means a method for measuring total lung capacity in which</u><br/>486&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>the subject breathes into a spirometer containing a known concentration of an inert and</u><br/>487&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>insoluble gas for a specific time, and the concentration of that inert and insoluble gas in the</u><br/>488&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>lung is compared to the concentration of that type of gas in the spirometer.</u><br/>489&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(37)  "Total lung capacity" means the volume of gas contained in the lungs at the end of</u><br/>490&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>a maximal inspiration.</u><br/>491&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(38)  "Veterans' benefits" means the same as that term is defined in Section</u><br/>492&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><a href="#78b-6-2003">78B-6-2003</a>.</u><br/><hr>493&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(39)  "Workers' compensation law" means the same as that term is defined in Section</u><br/>494&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><a href="#78b-6-2003">78B-6-2003</a>.</u> <br/>495&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 12.  Section <b>78B-6-2104</b><a name="78b-6-2104"></a> is enacted to read:<br/>496&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;78B-6-2104.</u></b>  <b>Filing claims -- Establishment of prima facie case -- Additional</b><br/>497&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>required information for new claims -- Individual actions to be filed. </b><br/>498&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(1)  A plaintiff in an asbestos or silica action shall file with the complaint or other initial</u><br/>499&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>pleading a detailed narrative medical report and diagnosis, signed under oath by a qualified</u><br/>500&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>physician and accompanied by supporting test results, which constitute prima facie evidence</u><br/>501&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>that the exposed person meets the requirements of this part.</u><br/>502&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(2)  The report described in Subsection (1) may not be prepared by a lawyer or person</u><br/>503&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>working for or on behalf of a lawyer or law firm.</u><br/>504&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(3)  For an asbestos or silica action pending on May 10, 2016, the detailed narrative</u><br/>505&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>medical report, diagnosis, and supporting test results described in Subsection (1) shall be</u><br/>506&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>provided to all parties not later than 90 days after May 10, 2016, or not later than 90 days</u><br/>507&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>before trial, whichever is earlier.</u><br/>508&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(4)  A defendant shall be afforded a reasonable opportunity to challenge the adequacy of</u><br/>509&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>the prima facie evidence before trial.</u><br/>510&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(5)  The court in an asbestos or silica action shall dismiss the action without prejudice</u><br/>511&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>on finding that the plaintiff has failed to make the prima facie showing required by this part.</u><br/>512&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(6)  A plaintiff in an asbestos or silica action filed on or after May 10, 2016, shall</u><br/>513&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>include a sworn information form containing all of the following:</u><br/>514&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(a)  the name, address, date of birth, social security number, marital status, occupation,</u><br/>515&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>and employer of the exposed person, and any person through which the exposed person alleges</u><br/>516&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>exposure;</u><br/>517&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(b)  the plaintiff's relationship to the exposed person or person through which the</u><br/>518&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>exposure is alleged;</u><br/>519&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(c)  the specific location and manner of each alleged exposure, including the specific</u><br/>520&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>location and manner of exposure for any person through which the exposed person alleges</u><br/>521&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>exposure;</u><br/>522&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(d)  the beginning and ending dates of each alleged exposure;</u><br/>523&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(e)  the identity of the manufacturer of the specific asbestos or silica product for each</u><br/><hr>524&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>exposure;</u><br/>525&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(f)  the identity of the defendant or defendants against whom the plaintiff asserts a</u><br/>526&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>claim;</u><br/>527&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(g)  the specific asbestos-related or silica-related disease claimed to exist; and</u><br/>528&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(h)  any supporting documentation relating to Subsections (6)(a) through (g).</u><br/>529&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(7)  Asbestos and silica actions shall be individually filed and may not be filed on</u><br/>530&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>behalf of a group or class of plaintiffs.</u> <br/>531&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 13.  Section <b>78B-6-2105</b><a name="78b-6-2105"></a> is enacted to read:<br/>532&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;78B-6-2105.</u></b>  <b>Elements of proof for asbestos actions alleging a nonmalignant</b><br/>533&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>asbestos-related condition. </b><br/>534&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(1)  An asbestos action related to an alleged nonmalignant asbestos-related condition</u><br/>535&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>may not be brought or maintained in the absence of prima facie evidence that the exposed</u><br/>536&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>person has a physical impairment for which asbestos exposure was a substantial contributing</u><br/>537&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>factor.</u><br/>538&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(2)  The prima facie showing shall be made as to each defendant and include a detailed</u><br/>539&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>narrative medical report and diagnosis signed under oath by a qualified physician that includes:</u><br/>540&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(a)  radiological or pathological evidence of asbestosis or radiological evidence of</u><br/>541&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>diffuse bilateral pleural thickening or a high-resolution computed tomography scan showing</u><br/>542&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>evidence of asbestosis or diffuse pleural thickening;</u><br/>543&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(b)  a detailed occupational and exposure history from the exposed person or, if that</u><br/>544&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>person is deceased, from the person most knowledgeable about the exposures that form the</u><br/>545&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>basis of the action, including identification of all of the exposed person's principal places of</u><br/>546&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>employment and exposures to airborne contaminants and whether each place of employment</u><br/>547&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>involved exposures to airborne contaminants, including asbestos fibers or other disease causing</u><br/>548&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>dusts or fumes, that may cause pulmonary impairment and the nature, duration, and level of</u><br/>549&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>any exposure;</u><br/>550&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(c)  a detailed medical, social, and smoking history from the exposed person or, if that</u><br/>551&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>person is deceased, from the person most knowledgeable about the exposures that form the</u><br/>552&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>basis of the action, including a thorough review of the past and present medical problems of the</u><br/>553&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>exposed person and the most probable cause of the medical problems;</u><br/>554&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(d)  evidence verifying that at least 15 years have elapsed between the exposed person's</u><br/><hr>555&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>date of first exposure to asbestos and the date of diagnosis;</u><br/>556&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(e)  evidence from a personal medical examination and pulmonary function testing of</u><br/>557&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>the exposed person, or if the exposed person is deceased, based upon the person's medical</u><br/>558&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>records, that the exposed person has or the deceased person had a permanent respiratory</u><br/>559&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>impairment rating of at least Class 2 as defined by and evaluated pursuant to the AMA Guides</u><br/>560&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>to the Evaluation of Permanent Impairment or reported significant changes year to year in lung</u><br/>561&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>function for FVC, FEV1, or DLCO as defined by the American Thoracic Society's</u><br/>562&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>interpretative strategies for lung function tests, 26 European Respiratory Journal 948-68,</u><br/>563&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>961-62, table 12 (2005), and as updated;</u><br/>564&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(f)  evidence that asbestosis or diffuse bilateral pleural thickening, rather than chronic</u><br/>565&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>obstructive pulmonary disease, is a substantial factor to the exposed person's physical</u><br/>566&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>impairment, based on a determination the exposed person has:</u><br/>567&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(i)  FVC below the predicted lower limit of normal and FEV1/FVC ratio (using actual</u><br/>568&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>values) at or above the predicted lower limit of normal;</u><br/>569&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(ii)  total lung capacity, by plethysmography or timed gas dilution, below the predicted</u><br/>570&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>lower limit of normal; or</u><br/>571&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(iii)  a chest x-ray showing bilateral small, irregular opacities (s, t, or u) graded by a</u><br/>572&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>certified B-reader as at least 2/1 on the ILO scale; and</u><br/>573&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(g)  the qualified physician signing the detailed narrative medical report described in</u><br/>574&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>this Subsection (2) has concluded that exposure to asbestos was a substantial contributing</u><br/>575&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>factor to the exposed person's physical impairment and not more probably the result of other</u><br/>576&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>causes.</u><br/>577&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(3)  A qualified physician's opinion that the medical findings and impairment are</u><br/>578&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>"consistent with" or "compatible with" exposure to asbestos, or words to that effect, does not</u><br/>579&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>satisfy the requirements described in Subsection (2)(g).</u> <br/>580&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 14.  Section <b>78B-6-2106</b><a name="78b-6-2106"></a> is enacted to read:<br/>581&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;78B-6-2106.</u></b>  <b>Elements of proof for asbestos actions alleging asbestos-related</b><br/>582&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>cancer other than mesothelioma. </b><br/>583&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(1)  An asbestos action for a mailignant condition other than mesothelioma may not be</u><br/>584&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>brought or maintained in the absence of prima facie evidence that the exposed person has a</u><br/>585&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>primary cancer for which exposure to asbestos was a substantial contributing factor.</u><br/><hr>586&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(2)  The prima facie showing shall be made as to each defendant and include a detailed</u><br/>587&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>narrative medical report and diagnosis signed under oath by a qualified physician, who is</u><br/>588&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>board-certified in pathology, pulmonary medicine or oncology, that includes:</u><br/>589&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(a)  radiological or pathological evidence of asbestosis or radiological evidence of</u><br/>590&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>diffuse bilateral pleural thickening or a high-resolution computed tomography scan showing</u><br/>591&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>evidence of asbestosis or diffuse bilateral pleural thickening;</u><br/>592&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(b)  evidence verifying that at least 15 years have elapsed between the exposed person's</u><br/>593&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>date of first exposure to asbestos and the date of diagnosis; and</u><br/>594&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(c)  the qualified physician signing the detailed narrative medical report described in</u><br/>595&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>this Subsection (2) has concluded that exposure to asbestos was a substantial contributing</u><br/>596&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>factor to the cancer of the exposed person and not more probably the result of other causes.</u><br/>597&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(3)  A qualified physician's opinion stating that the medical findings and cancer are</u><br/>598&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>"consistent with" or "compatible with" exposure to asbestos, or words to that effect, does not</u><br/>599&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>satisfy the requirement described in Subsection (2)(c).</u><br/>600&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(4)  The court shall hold an evidentiary hearing and determine if the exposed person has</u><br/>601&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>established a prima facie showing of cancer to which exposure to asbestos was a substantial</u><br/>602&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>contributing factor.</u> <br/>603&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 15.  Section <b>78B-6-2107</b><a name="78b-6-2107"></a> is enacted to read:<br/>604&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;78B-6-2107.</u></b>  <b>Elements of proof for silica actions alleging silicosis. </b><br/>605&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(1)  A silica action related to alleged silicosis may not be brought or maintained in the</u><br/>606&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>absence of prima facie evidence that the exposed person has a physical impairment as a result</u><br/>607&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>of silicosis.</u><br/>608&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(2)  The prima facie showing shall be made as to each defendant and include a detailed</u><br/>609&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>narrative medical report and diagnosis signed under oath by a qualified physician that includes:</u><br/>610&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(a)  radiological or pathological evidence of silicosis or a high-resolution computed</u><br/>611&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>tomography scan showing evidence of silicosis;</u><br/>612&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(b)  a detailed occupational and exposure history from the exposed person or, if the</u><br/>613&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>exposed person is deceased, from the person most knowledgeable about the exposures that</u><br/>614&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>form the basis of the action, including identification of all principal places of employment and</u><br/>615&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>exposures to airborne contaminants and whether each place of employment involved exposures</u><br/>616&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>to airborne contaminants, including silica or other disease-causing dusts or fumes, that may</u><br/><hr>617&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>cause pulmonary impairment and the nature, duration, and level of any exposure;</u><br/>618&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(c)  a detailed medical, social, and smoking history from the exposed person or, if the</u><br/>619&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>exposed person is deceased, from the person most knowledgeable about the exposures that</u><br/>620&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>form the basis of the action, including a thorough review of the past and present medical</u><br/>621&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>problems and the most probable cause of the medical problems;</u><br/>622&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(d)  evidence that a sufficient latency period has elapsed between the exposed person's</u><br/>623&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>date of first exposure to silica and the day of diagnosis;</u><br/>624&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(e)  evidence based upon a personal medical examination and pulmonary function</u><br/>625&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>testing of the exposed person, or if the exposed person is deceased, based upon the person's</u><br/>626&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>medical records, that the exposed person has or the deceased person had a permanent</u><br/>627&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>respiratory impairment rating of at least Class 2 as defined by and evaluated pursuant to the</u><br/>628&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>AMA Guides to the Evaluation of Permanent Impairment or reported significant changes year</u><br/>629&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>to year in lung function for FVC, FEV1, or DLCO as defined by the American Thoracic</u><br/>630&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Society's interpretative strategies for lung function tests, 26 European Respiratory Journal</u><br/>631&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>948-68, 961-62, table 12 (2005), and as updated; and</u><br/>632&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(f)  the qualified physician signing the detailed narrative medical report in this</u><br/>633&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Subsection (2) has concluded that exposure to silica was a substantial contributing factor to the</u><br/>634&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>exposed person's physical impairment and not more probably the result of other causes.</u><br/>635&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(3)  A qualified physician's opinion stating that the medical findings and impairment are</u><br/>636&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>"consistent with" or "compatible with" exposure to silica, or words to that effect, does not</u><br/>637&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>satisfy the requirement in Subsection (2)(f).</u> <br/>638&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 16.  Section <b>78B-6-2108</b><a name="78b-6-2108"></a> is enacted to read:<br/>639&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;78B-6-2108.</u></b>  <b>Elements of proof for silica actions other than silicosis. </b><br/>640&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(1)  A silica action other than silicosis may not be brought or maintained in the absence</u><br/>641&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>of prima facie evidence that the exposed person has a primary cancer or physical impairment</u><br/>642&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>for which exposure to silica was a substantial contributing factor.</u><br/>643&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(2)  The prima facie showing shall be made as to each defendant and include a detailed</u><br/>644&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>narrative medical report and diagnosis signed under oath by a qualified physician, who is</u><br/>645&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>board-certified in pathology, pulmonary medicine or oncology, that includes:</u><br/>646&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(a)  radiological or pathological evidence of silicosis or a high-resolution computed</u><br/>647&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>tomography scan showing evidence of silicosis;</u><br/><hr>648&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(b)  evidence verifying that at least 15 years have elapsed between the exposed person's</u><br/>649&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>date of first exposure to silica and the date of diagnosis; and</u><br/>650&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(c)  the qualified physician signing the detailed narrative medical report in this</u><br/>651&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Subsection (2) has concluded that exposure to silica was a substantial contributing factor to the</u><br/>652&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>exposed person's primary cancer or physical impairment and not more probably the result of</u><br/>653&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>other causes.</u><br/>654&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(3)  A qualified physician's opinion stating that the medical findings and primary cancer</u><br/>655&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>or physical impairment are "consistent with" or "compatible with" exposure to silica, or words</u><br/>656&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>to that effect, does not satisfy the requirement described in Subsection (2)(c).</u><br/>657&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(4)  The court shall hold an evidentiary hearing and determine if the exposed person has</u><br/>658&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>established a prima facie showing of a primary cancer or physical impairment to which</u><br/>659&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>exposure to silica was a substantial contributing factor.</u> <br/>660&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 17.  Section <b>78B-6-2109</b><a name="78b-6-2109"></a> is enacted to read:<br/>661&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;78B-6-2109.</u></b>  <b>Elements of physical impairment. </b><br/>662&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Evidence relating to physical impairment under this part, including pulmonary function</u><br/>663&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>testing and diffusing studies, offered in an action governed by this part, shall satisfy the</u><br/>664&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>following requirements:</u><br/>665&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(1)  the evidence shall comply with the quality controls, equipment requirements,</u><br/>666&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>methods of calibration and techniques set forth in the AMA Guides to the Evaluation of</u><br/>667&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Permanent Impairment, and all standards set forth in the official statements of the American</u><br/>668&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Thoracic Society, which are in effect on the date of any examination or pulmonary function</u><br/>669&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>testing of the exposed person required by this part;</u><br/>670&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(2)  the evidence may not be obtained by, or based on, testing or examinations that</u><br/>671&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>violate any law, regulation, licensing requirement, or medical code of practice of the state in</u><br/>672&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>which the examination, test, or screening was conducted, or of this state; and</u><br/>673&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(3)  the evidence may not be obtained under the condition that the plaintiff or exposed</u><br/>674&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>person retains the legal services of the attorney or law firm sponsoring the examination, test, or</u><br/>675&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>screening.</u> <br/>676&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 18.  Section <b>78B-6-2110</b><a name="78b-6-2110"></a> is enacted to read:<br/>677&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;78B-6-2110.</u></b>  <b>Procedures. </b><br/>678&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(1)  The existence of evidence relating to the prima facie showings required in this part</u><br/><hr>679&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>does not create a presumption that the exposed person has an asbestos-related or silica-related</u><br/>680&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>injury or impairment and may not be conclusive as to the liability of any defendant.</u><br/>681&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(2)  Evidence may not be offered at trial, and the jury may not be informed, of:</u><br/>682&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(a)  the grant or denial of a motion to dismiss an asbestos or silica action under the</u><br/>683&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>provisions of this part; or</u><br/>684&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(b)  the provisions of this part with respect to what constitutes a prima facie showing of</u><br/>685&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>asbestos or silica-related impairment.</u><br/>686&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(3)  Until a court enters an order determining that the exposed person has established</u><br/>687&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>prima facie evidence of impairment, an asbestos or silica action may not be subject to</u><br/>688&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>discovery, except:</u><br/>689&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(a)  discovery related to establishing or challenging the prima facie evidence; or</u><br/>690&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(b)  by order of the trial court upon motion of a party and for good cause shown.</u><br/>691&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(4) (a)  A court may consolidate for trial any number and type of asbestos or silica</u><br/>692&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>actions with the consent of all the parties.</u><br/>693&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(b)  In the absence of consent described in Subsection (4)(a), the court may consolidate</u><br/>694&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>for trial only asbestos or silica actions relating to the exposed person and members of that</u><br/>695&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>person's household.</u><br/>696&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(c)  No class action or any other form of mass aggregation relating to more than one</u><br/>697&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>exposed person and members of those persons' households may be permitted.</u><br/>698&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(d)  The provisions of this Subsection (4) do not preclude consolidation of cases by</u><br/>699&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>court order for pretrial or discovery purposes.</u> <br/>700&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 19.  Section <b>78B-6-2111</b><a name="78b-6-2111"></a> is enacted to read:<br/>701&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;78B-6-2111.</u></b>  <b>Limitations on liability in asbestos and silica actions. </b><br/>702&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(1)  A premises owner, or any entity performing operations on a premises, is not liable</u><br/>703&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>in an asbestos or silica action for exposures that do not occur on the premises.</u><br/>704&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(2)  A defendant in an asbestos or silica action may not be liable for exposures from a</u><br/>705&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>product or component part made or sold by a third party, even if the third party is insolvent or</u><br/>706&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>otherwise not amenable to suit.</u><br/>707&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(3)  Punitive damages may not be awarded in an asbestos or silica action.</u> <br/>708&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 20.  Section <b>78B-6-2112</b><a name="78b-6-2112"></a> is enacted to read:<br/>709&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;78B-6-2112.</u></b>  <b>Requirements for proof of causation. </b><br/><hr>710&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>The following standards for proof of causation apply in any asbestos action involving</u><br/>711&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>multiple sources of exposures:</u><br/>712&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(1)  proof of "any exposure" to a defendant's product may not suffice and instead the</u><br/>713&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>plaintiff shall establish the dose of asbestos fibers to which the exposed person was exposed to</u><br/>714&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>from each defendant's product;</u><br/>715&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(2)  the dose shall be quantified but need not be established with mathematical</u><br/>716&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>precision;</u><br/>717&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(3)  the plaintiff shall establish that the defendant's product was a substantial factor in</u><br/>718&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>causing the plaintiff's disease;</u><br/>719&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(4)  the defendant's product is not a substantial factor in causing the plaintiff's disease if,</u><br/>720&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>in light of the evidence of the plaintiff's total exposure to asbestos or other toxins, reasonable</u><br/>721&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>persons would not regard the defendant's product as a cause of the disease; and</u><br/>722&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(5)  the plaintiff, in the absence of direct evidence of causation, shall prove substantial</u><br/>723&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>factor causation with scientifically reliable expert testimony that the plaintiff's exposure to the</u><br/>724&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>defendant's product more than doubled the plaintiff's risk of contracting the disease.</u> <br/>725&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 21.  Section <b>78B-6-2113</b><a name="78b-6-2113"></a> is enacted to read:<br/>726&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;78B-6-2113.</u></b>  <b>Statute of limitations -- Two-disease rule. </b><br/>727&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(1)  The period of limitations for an asbestos or silica action that is not barred as of May</u><br/>728&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>10, 2016, may not accrue, nor may the running of limitations commence, prior to the earlier of</u><br/>729&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>the date the exposed person:</u><br/>730&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(a)  received a medical diagnosis of an asbestos-related impairment or silica-related</u><br/>731&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>impairment;</u><br/>732&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(b)  discovered facts that would have led a reasonable person to obtain a medical</u><br/>733&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>diagnosis with respect to the existence of an asbestos-related impairment or silica-related</u><br/>734&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>impairment; or</u><br/>735&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(c)  died having an asbestos-related or silica-related impairment.</u><br/>736&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(2)  Nothing in this section may be construed to revive or extend limitations with</u><br/>737&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>respect to any claim for asbestos- or silica-related impairment that was otherwise time-barred</u><br/>738&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>as of May 10, 2016.</u><br/>739&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(3)  Nothing in this section may be construed to adversely affect, impair, limit, modify,</u><br/>740&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>or nullify any settlement or other agreements with respect to an asbestos or silica action entered</u><br/><hr>741&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>into before May 10, 2016.</u><br/>742&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(4)  An asbestos or silica action arising out of a nonmalignant condition shall be a</u><br/>743&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>distinct cause of action from an action for an asbestos-related or silica-related cancer.</u><br/>744&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(5)  If otherwise permitted under state law, damages may not be awarded in an asbestos</u><br/>745&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>or silica action for fear of increased risk of future disease.</u> <br/>746&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 22.  Section <b>78B-6-2114</b><a name="78b-6-2114"></a> is enacted to read:<br/>747&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;78B-6-2114.</u></b>  <b>Application. </b><br/>748&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(1)  This part applies to asbestos and silica actions filed on or after May 10, 2016, as</u><br/>749&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>well as any pending asbestos and silica actions in which trial has not commenced as of May 10,</u><br/>750&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>2016.</u><br/>751&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(2)  This part may only be applied prospectively if the application of a provision in this</u><br/>752&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>part would unconstitutionally affect a vested right.</u> <br/><br/><hr style="width:90%; color: #333; text-align: right" /><br/><hr style="width:90%; color: #333; text-align: right" /><br/><br/><b>Legislative Review Note<br/>Office of Legislative Research and General Counsel</b>
</font>
</div>
</body>
</html>
